Skip to main content

Advertisement

SpringerLink
Log in

Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine

  • Review
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Migraine is one of the most prevalent neurological disorders known to have an immense adverse socio-economic impact. Neurogenic inflammation is thought to mediate migraine, and CGRP is known to be released during acute attacks of migraine that causes vasodilation in extracerebral arteries. Hence, CGRP is believed to play a key role in triggering migraine. Although there are several classes of medications used in the prevention and treatment of migraine pain, targeted therapies are fewer. Therefore, CGRP receptor inhibitors which bind to CGRP receptors in the cranial vasculature have been developed as drugs for migraine therapy. In this review article, we describe the basic pathophysiologic mechanism that causes migraine headaches and the pharmacotherapeutic aspects of CGRP inhibitors available for clinical use. For the purpose of this review, a search was performed on the pharmacological, pharmacokinetic, pharmaceutical, and therapeutic aspects of the FDA-approved CGRP inhibitors viz. erenumab, ubrogepant, rimegepant, atogepant, eptinezumab, fremanezumab, and galcanezumab in UpToDate database and PubMed beginning year 2000. Based on the data collected, a risk–benefit comparison of different classes of novel CGRP inhibitors available for clinical use is provided. This comparative review may help the healthcare providers in choosing the best pharmacotherapeutic agent for their patients based on patient-specific information.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

This is a review article based on previosuly published data and databases that have been appropriately cited in the article itself.

References

  • Broner SW, Bobker S, Klebanoff L (2017) Migraine in women. Semin Neurol 37(6):601–610

    Article  PubMed  Google Scholar 

  • Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008

    Article  CAS  PubMed  Google Scholar 

  • Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W (2000) Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420–423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Durham PL, Vause CV (2010) Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 24(7):539–548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Edvinsson L, Haanes KA, Warfvinge K (2019) Does inflammation have a role in migraine? Nat Rev Neurol 15(8):483–490

    Article  PubMed  Google Scholar 

  • Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P (2009) Future drugs for migraine. Intern Emerg Med 4(5):367–373

    Article  PubMed  Google Scholar 

  • Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33(1):48–56

    Article  CAS  PubMed  Google Scholar 

  • Goadsby PJ, Edvinsson L (1994) Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34(7):394–399

    Article  CAS  PubMed  Google Scholar 

  • Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132

    Article  CAS  PubMed  Google Scholar 

  • Hargreaves R, Olesen J (2019) Calcitonin gene-related peptide modulators - the history and renaissance of a new migraine drug class. Headache 59(6):951–970

    Article  PubMed  Google Scholar 

  • Hershey AD (2017) CGRP - The next frontier for migraine. N Engl J Med 377(22):2190–2191

    Article  PubMed  Google Scholar 

  • Huang T, Xu Y, Chen Y, Bian J, Chu Z, Zhao S (2022) Ma L Efficacy and safety of calcitonin gene-related peptide antagonists in migraine treatment: a meta-analysis. Brain Behav 12(4):e2542

    Article  PubMed  PubMed Central  Google Scholar 

  • Iyengar S, Johnson KW, Ossipov MH, Aurora SK (2019) CGRP and the trigeminal system in migraine. Headache 59(5):659–681

    Article  PubMed  PubMed Central  Google Scholar 

  • Jacobs B, Dussor G (2016) Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience 338:130–144

    Article  CAS  PubMed  Google Scholar 

  • Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kursun Q, Yemisci M, van den Maagdenberg AMJM, Hulya KH (2021) Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain 22(1):55

    Article  PubMed  PubMed Central  Google Scholar 

  • Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22(1):54–61

    Article  CAS  PubMed  Google Scholar 

  • Neurology Live. https://www.neurologylive.com/view/atogepant-effectively-prevents-migraine-in-phase-2b3-trial. Accessed February 28, 2022.

  • Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34(2):114–125

    Article  PubMed  Google Scholar 

  • Mercer SE, Chaturvedula PV, Conway CM, Cook DA, Davis CD, Pin SS, Macci R, Schartman R, Signor LJ, Widmann KA, Whiterock VJ, Xu PCC, Herbst JJ, Kostich WA, Thalody G, Macor JE, Dubowchik GM (2021) Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett 31:127624

    Article  CAS  PubMed  Google Scholar 

  • Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110

    Article  CAS  PubMed  Google Scholar 

  • Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; July 30, 2021. https://online.lexi.com. Accessed December 30, 2021.

  • Raffaelli B, Reuter U (2018) The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics 15(2):324–335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ramachandran R (2018) Neurogenic inflammation and its role in migraine. Semin Immunopathol 40(3):301–314

    Article  CAS  PubMed  Google Scholar 

  • Rees TA, Hendrikse ER, Hay DL, Walker CS (2022) Beyond CGRP: the calcitonin peptide family as targets for migraine and pain. Br J Pharmacol 79(3):381–399

    Article  Google Scholar 

  • Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280–2287

    Article  CAS  PubMed  Google Scholar 

  • Russo AF (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol 55:533–552

    Article  CAS  PubMed  Google Scholar 

  • Sacco S, Olivieri L, Bastianello S, Carolei A (2006) Comorbid neuropathologies in migraine. J Headache Pain 7(4):222–230

    Article  PubMed  PubMed Central  Google Scholar 

  • Saper J, Lipton R, Kudrow D, Hirman J, Dodick D, Silberstein S, Chakhava G, Smith J. Primary Results of PROMISE-1 (Prevention of Migraine via Intravenous eptinezumab Safety and Efficacy–1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Episodic Migraines (S20.001). 2018; 90 (15 Supplement).

  • Sevivas H, Fresco P (2022) Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. Eur J Med Res 27(1):86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434

    Article  CAS  PubMed  Google Scholar 

  • Tepper SJ, Diener H, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD (2019) Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology 92(20):e2309–e2320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D (2016) A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36(9):887–898

    Article  PubMed  Google Scholar 

  • Yang C, Liang C, Chang C, Yang C, Shih P, Yau Y, Tang K, Wang S (2021a) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2128544

    Article  PubMed  PubMed Central  Google Scholar 

  • Yang C, Zeng B, Chang C, Shih P, Wang S (2021b) Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine: a network meta-analysis of randomized controlled trials. Neurotherapeutics 18(4):2639–2650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This is a review of literature, and I did not receive any funding for this study.

Author information

Authors and Affiliations

  1. West Haven Pharmacy, West Haven, CT, 06516, USA

    Sandhya Jinesh

Authors
  1. Sandhya Jinesh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandhya Jinesh.

Ethics declarations

Conflict of interest

A competing interests declaration is mandatory for publication in this journal. Please confirm that this declaration is accurate, or provide an alternative.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jinesh, S. Pharmaceutical aspects of novel CGRP inhibitors used in the prophylaxis and treatment of migraine. Inflammopharmacol 31, 2245–2251 (2023). https://doi.org/10.1007/s10787-023-01276-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-023-01276-z

Keywords

Search

Navigation